Navigation Links
Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke

Neurobiological Technologies, Inc. (NTI) announced today the presentation of new analysis of data from prior clinical trials of ancrod and updates on the clinical development of their investigational drug, Viprinex(TM) (ancrod), for the treatment of acute ischaemic stroke at the 16th annual European Stroke Congress in Glasgow, Scotland in the United Kingdom. Viprinex is a defibrinogenating agent derived from the venom of the Malayan pit viper.

"The ancrod data presented this week in Glasgow draws positive conclusions that support a new dosing regimen for ancrod and revised inclusion/exclusion criteria for the current clinical trials," said David Sherman, MD, University of Texas Health Science Center at San Antonio, USA.

"The reanalysis enables us to see that ancrod may be safe and effective when administered to patients within six hours of stroke onset. With so few treatments currently available to stroke patients, we look forward to the results of the international phase 3 trials. We hope the phase 3 results provide evidence of definitive safety and efficacy of ancrod in ischaemic stroke in the six-hour time window."

NTI is moving forward with two international, randomized, double-blind, placebo-controlled phase 3 trials for Viprinex(TM) as part of the Ancrod Stroke Program (ASP). These trials, known as ASP-I and ASP-II, will evaluate whether a brief (2 or 3 hour) infusion of ancrod begun up to six hours after onset of stroke can reduce stroke related disability. ASP-I and II are currently enrolling and each trial is planned to enroll 650 patients. Patient accrual began in November 2005.

The trials are being conducted in the U.S., Europe, South Africa, Australia, and New Zealand. Additional countries will be entering the program. The company expects that the trials will be conducted at up to 130 sites worldwide and that approximately 70% of the ASP-I sites and approximately 50% of the ASP-II sites will be lo cated within the U.S. Patients who qualify for enrollment into the clinical trials will receive a two or three-hour intravenous infusion of ancrod or placebo within six hours of stroke onset. If treated within three hours of stroke onset, subjects must have been determined unsuitable for treatment with tPA.

"We have data showing that fibrinogen plays a significant role in influencing stroke outcome. Ancrod directly targets fibrinogen and has the potential to treat strokes by rapidly lowering fibrinogen levels," said David E. Levy, MD, Vice President of Clinical Development for NTI.

"We are aggressively recruiting patients worldwide for the ASP-I and ASP-II studies. We hope by garnering a large patient base for the study we can generate the robust data needed to confirm our new dosing strategy and six hour treatment window for acute ischaemic stroke."


'"/>




Related medicine news :

1. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
2. New Drug Application Submitted for Investigational Antibiotic Doripenem
3. Overweight Kids At Risk Of Being Iron Deficient
4. Solutions Being Sought For Prevention Of Rickets
5. Being Overweight Could Lead To Irregular Heartbeats
6. Being Obese Increases Ones Risk Of A wrong Diagnosis During Medical Imaging
7. Being Obese Could Lead To Kidney Stone Formation
8. Patients Suffering From Severe Mental Diseases Are At Risk Of Being Crime Victims
9. Being together matters, both in marriage and smoking
10. Being Lonely is gene regulated
11. Heart Functions Being Redefined By Researchers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... June 23, 2017 , ... The Katyl Agency, a locally ... and business owners in and around Lackawanna County, is joining Meals On Wheels ... area. , Meals on Wheels of NEPA provides hand-delivered and nutritious meals to ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... All-Star Insurance, ... residential and business clients throughout eastern Texas, is announcing the launch of a new ... Recent breast cancer statistics in the United States reveal that an estimated 252, 710 ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... the Houston area with access to asset protection and financial planning services, is ... aimed at improving the lives of children with cancer and other chronic diseases. ...
(Date:6/22/2017)... ... June 22, 2017 , ... Plastic Surgery Associates is proud to ... for 2017. Each year, research and information firm, Castle Connolly, releases their list of ... 2015, this marks the 3rd time that Dr. Canales has been recognized ...
(Date:6/22/2017)... ... , ... Groove Ring is excited to announce they've partnered with Olympic runner ... and all-purpose rings. Whether you’re an athlete, adventurer, professional, or love to venture the ... From the rock face to the auto shop, Groove Ring is the world's first ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: